Teleflex (TFX)
(Delayed Data from NYSE)
$239.18 USD
-0.36 (-0.15%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $239.20 +0.02 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$239.18 USD
-0.36 (-0.15%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $239.20 +0.02 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth B Momentum C VGM
Zacks News
Here's Why Teleflex (TFX) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Teleflex (TFX) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Teleflex (TFX) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Teleflex (TFX) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Teleflex (TFX) Expands Vascular Access Portfolio With New Launch
by Zacks Equity Research
Teleflex (TFX) debuts the new Arrow EZ-IO Intraosseous Access Procedure Tray.
Unlocking Teleflex (TFX) International Revenues: Trends, Surprises, and Prospects
by Zacks Equity Research
Evaluate Teleflex's (TFX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Teleflex (TFX) Q1 Earnings Beat Estimates, Margins Rise
by Zacks Equity Research
Teleflex's (TFX) first-quarter 2024 results reflect growth across the majority of the company's product families in EMEA.
Compared to Estimates, Teleflex (TFX) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teleflex (TFX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 4.56% and 1.54%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?
by Urmimala Biswas
Here is a sneak peek into how the five MedTech stocks, HOLX, ZBH, ILMN, TFX and BRKR, are expected to fare in their quarterly results slated to be released tomorrow.
Ahead of Teleflex (TFX) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Teleflex (TFX) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATC
by Zacks Equity Research
Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.
Is ALPS O'Shares U.S. Small-Cap Quality Dividend ETF (OUSM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OUSM
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) on robust growth in the Vascular business and strong Urolift prospects.
Should ALPS O'Shares U.S. Small-Cap Quality Dividend ETF (OUSM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for OUSM
Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Falls
by Zacks Equity Research
Teleflex (TFX) surpasses earnings and revenue estimates in the fourth quarter of 2023.
Compared to Estimates, Teleflex (TFX) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Teleflex (TFX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 3.68% and 0.71%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
LivaNova (LIVN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 10.13% and 6.94%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Countdown to Teleflex (TFX) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Teleflex (TFX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 12.90% and 0.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Teleflex (TFX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mesa Labs (MLAB) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of -0.98% and 2.60%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?